In patients with head and neck cancer, PD-1 therapy enhances the functionality of cetuximab-activated PD-1+NK cells by inhibiting interactions with PD-L1-expressing tumor cells (Concha-Benavente et al., 2018). This evidence concerns the gene CD274 and head and neck cancer.